67318 Federal Register / Vol. 88, No. 188 / Friday, September 29, 2023 / Notices 

Court of Federal Claims No: 23–1326V 

54. Silvia Aguayo, Lancaster, California, 

Court of Federal Claims No: 23–1327V 

55. Katie B. Tate, Los Angeles, California, 

Court of Federal Claims No: 23–1342V 

56. Savana Torres, Los Angeles, California, 

Court of Federal Claims No: 23–1343V 

57. Linda Orbanac, Sayre, Pennsylvania, 

Court of Federal Claims No: 23–1344V 

58. Angela Battles, White, Georgia, Court of 

Federal Claims No: 23–1345V 

59. Mark E. Hanson, Minneapolis, Minnesota, 

Court of Federal Claims No: 23–1346V 

60. Beata Brozek, Evanston, Illinois, Court of 

Federal Claims No: 23–1347V 

61. Melissa Thomas on behalf of M. T., 

Wilmington, North Carolina, Court of 

Federal Claims No: 23–1351V 

62. Danyel Nelson, Warwick, Rhode Island, 

Court of Federal Claims No: 23–1352V 

63. John Schouest, Thibodaux, Louisiana, 

Court of Federal Claims No: 23–1353V 

64. Nicole Sicuro-Leipski on behalf of G. L., 

Kenosha, Wisconsin, Court of Federal 

Claims No: 23–1356V 

65. Shalonda Goolsby, Dresher, 

Pennsylvania, Court of Federal Claims 

No: 23–1357V 

66. Alice McCarthy, Renton, Washington, 

Court of Federal Claims No: 23–1360V 

67. Yesid Hernandez, Naples, Florida, Court 

of Federal Claims No: 23–1364V 

68. Leah Keller, Washington, District of 

Columbia, Court of Federal Claims No: 

23–1367V 

69. Bethel Stevens, Waimea, Hawaii, Court of 

Federal Claims No: 23–1369V 

70. Dolores Jefferson, Fairburn, Georgia, 

Court of Federal Claims No: 23–1370V 

71. Dawn Ferris-Murray, Mount Laurel, New 

Jersey, Court of Federal Claims No: 23– 

1380V 

72. Jeremy Allred, Minneapolis, Minnesota, 

Court of Federal Claims No: 23–1385V 

73. Mary Louise Spann, Nashville, 

Tennessee, Court of Federal Claims No: 

23–1395V 

74. Vincent Russell, West Chester, 

Pennsylvania, Court of Federal Claims 

No: 23–1397V 

75. Larry Cunningham, Aurora, Colorado, 

Court of Federal Claims No: 23–1404V 

76. Chinyere Jumbo, Hoover, Alabama, Court 

of Federal Claims No: 23–1419V 

77. Chinyere Jumbo, Hoover, Alabama, Court 

of Federal Claims No: 23–1421V 

78. Leora Chasen, Binghamton, New York, 

Court of Federal Claims No: 23–1423V 

79. Steven Hofmaster, Camas, Washington, 

Court of Federal Claims No: 23–1430V 

80. Aislynn Hayes, Murfreesboro, Tennessee, 

Court of Federal Claims No: 23–1448V 

81. Bobby Rossette, Boston, Massachusetts, 

Court of Federal Claims No: 23–1477V 

82. Maria Bettinger, Houston, Texas, Court of 

Federal Claims No: 23–1478V 

83. Candy Guzman-Guizar, Alhambra, 

California, Court of Federal Claims No: 

23–1484V 

84. Brian Andrew Vergara, Phoenix, Arizona, 

Court of Federal Claims No: 23–1486V 

85. Yoshua Rozen, Boston, Massachusetts, 

Court of Federal Claims No: 23–1487V 

86. Kristen Edwards Dempsey, Honolulu, 

Hawaii, Court of Federal Claims No: 23– 

1493V 

87. Andrea Mae Warren, Honolulu, Hawaii, 

Court of Federal Claims No: 23–1494V 

88. Gina Lewis, Sterling, Kansas, Court of 

Federal Claims No: 23–1495V 

89. Ollie Phillips, Woodridge, Illinois, Court 

of Federal Claims No: 23–1496V 

90. Elizabeth Herman, West Chester, 

Pennsylvania, Court of Federal Claims 

No: 23–1497V 

91. John Bovard, Boston, Massachusetts, 

Court of Federal Claims No: 23–1498V 

92. Kandi Shafer, Woodridge, Illinois, Court 

of Federal Claims No: 23–1499V 

93. John Yankey, Canby, Oregon, Court of 

Federal Claims No: 23–1500V 

94. Tynh Maejlauk, Chandler, Arizona, Court 

of Federal Claims No: 23–1501V 

95. Linda Shaw, DeLand, Florida, Court of 

Federal Claims No: 23–1502V 

96. Lashay Cameron on behalf of N. C., Jr., 

Deceased, Aventura, Florida, Court of 

Federal Claims No: 23–1505V 

97. Rebecca Furdell, Cape Coral, Florida, 

Court of Federal Claims No: 23–1506V 

98. Margaret Covino, Worcester, 

Massachusetts, Court of Federal Claims 

No: 23–1508V 

99. Bartolomeo Marano, Boston, 

Massachusetts, Court of Federal Claims 

No: 23–1509V 

100. Lynda Speer, Washington, District of 

Columbia, Court of Federal Claims No: 

23–1511V 

[FR Doc. 2023–21498 Filed 9–28–23; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Notice of Request for Public 

Comments on a Draft 

Recommendation To Update the 

HRSA-Supported Women’s Preventive 

Services Guideline Relating to 

Screening for Urinary Incontinence 

AGENCY: Health Resources and Services 

Administration (HRSA), U. S. 

Department of Health and Human 

Services. 

ACTION: Notice. 

SUMMARY: This notice seeks comments 

on a draft recommendation to update 

the HRSA-supported Women’s 

Preventive Services Guidelines 

(‘‘Guidelines’’) relating to Screening for 

Urinary Incontinence. This draft 

recommendation has been developed 

through a cooperative agreement, 

known as the Women’s Preventive 

Services Initiative (WPSI), with the 

American College of Obstetricians and 

Gynecologists (ACOG), through which 

they convene health professionals to 

develop draft recommendations. Under 

applicable law, non-grandfathered 

group health plans and health insurance 

issuers must include coverage, without 

cost sharing, for certain preventive 

services, including those provided for in 

the HRSA-supported Guidelines. The 

Departments of Labor, Health and 

Human Services, and Treasury have 

previously issued regulations, which 

describe how group health plans and 

health insurance issuers apply the 

coverage requirements. 

DATES: Members of the public are 

invited to provide written comments no 

later than October 30, 2023. All 

comments received on or before this 

date will be reviewed and considered by 

WPSI and provided for further 

consideration by HRSA in determining 

the recommended update that it will 

support. 

ADDRESSES: Members of the public who 

wish to provide comments can do so by 

accessing the public comment web page 

at https://www.womenspreventive

health.org/. 

FOR FURTHER INFORMATION CONTACT: 

Kimberly Sherman, HRSA, Maternal 

and Child Health Bureau, telephone 

(301) 443–8283, email: wellwomancare@

hrsa.gov. 

SUPPLEMENTARY INFORMATION: Under 

section 1001(5) of the Patient Protection 

and Affordable Care Act, Public Law 

111–148, which added section 2713 to 

the Public Health Service Act, 42 U.S.C. 

300gg-13, the preventive care and 

screenings set forth in the Guidelines 

are required to be covered without costsharing by certain group health plans 

and health insurance issuers. HRSA 

established the Guidelines in 2011 

based on expert recommendations by 

the Institute of Medicine, now known as 

the National Academy of Medicine, 

developed under a contract with the 

Department of Health and Human 

Services. Since 2011, there have been 

advancements in science and gaps 

identified in these guidelines, including 

a greater emphasis on practice-based 

clinical considerations. Since 2016, 

HRSA has funded cooperative 

agreements with ACOG for WPSI to 

convene a coalition representing 

clinicians, academics, and consumerfocused health professional 

organizations to conduct a rigorous 

review of current scientific evidence, 

solicit and consider public input, and 

make recommendations to HRSA 

regarding updates to the Guidelines to 

improve women’s health across the 

lifespan. HRSA then determines 

whether to support, in whole or in part, 

the recommended updates to the 

Guidelines. WPSI consists of an 

Advisory Panel and two expert 

committees, the Multidisciplinary 

Steering Committee and the 

Dissemination and Implementation 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 88, No. 188 / Friday, September 29, 2023 / Notices 67319 

Steering Committee, which are 

comprised of a broad coalition of 

organizational representatives who are 

experts in disease prevention and 

women’s health issues. With oversight 

by the Advisory Panel, and with input 

from the Multidisciplinary Steering 

Committee, WPSI examines the 

evidence to develop new (and update 

existing) recommendations for women’s 

preventive services. WPSI’s 

Dissemination and Implementation 

Steering Committee takes HRSAapproved recommendations and 

disseminates them through the 

development of implementation tools 

and resources for both patients and 

practitioners. 

WPSI bases its recommended updates 

to the Guidelines on review and 

synthesis of existing clinical guidelines 

and new scientific evidence, following 

the National Academy of Medicine 

standards for establishing foundations 

for and rating strengths of 

recommendations, articulation of 

recommendations, and external reviews. 

Additionally, HRSA requires that WPSI 

incorporate processes to assure 

opportunity for public comment, 

including participation by patients and 

consumers, in the development of its 

recommendations to the updated 

Guidelines. 

The Existing Guideline States 

‘‘Screening for Urinary Incontinence 

WPSI recommends screening women 

for urinary incontinence annually. 

Screening should ideally assess whether 

women experience urinary incontinence 

and whether it impacts their activities 

and quality of life. The Women’s 

Preventive Services Initiative 

recommends referring women for 

further evaluation and treatment if 

indicated.’’ 

Draft Updated Clinical 

Recommendation for Public Comment 

‘‘Screening for Urinary Incontinence 

The Women’s Preventive Services 

Initiative recommends screening women 

for urinary incontinence annually. 

Screening should assess whether 

women experience urinary incontinence 

and whether it impacts their activities 

and quality of life. If indicated, 

facilitating further evaluation and 

treatment is recommended.’’ 

Discussion of Draft Updated Clinical 

Recommendation 

WPSI recommended several minor 

updates to the language of this 

Guideline. First, the word ‘‘ideally’’ is 

recommended to be removed from the 

second sentence for brevity, and its 

removal, if accepted by HRSA, will not 

substantively change the existing 

guideline. Second, the final sentence of 

the clinical recommendation 

recommends changing the word 

‘‘referring’’ to ‘‘facilitating’’ to reflect 

that clinicians in practice, after 

screening for urinary incontinence, may 

decide to treat or manage urinary 

incontinence as part of standard 

primary care services or refer to 

specialists if specialist care is needed. 

Lastly, WPSI recommended minor edits 

to the language of the Guideline for the 

purposes of clarity. These minor edits 

have no substantive effect on the 

requirement for coverage without costsharing. 

Members of the public can view the 

complete updated draft 

recommendation, which includes the 

implementation considerations and 

research recommendations, by accessing 

the initiative’s web page at https:// 

www.womenspreventivehealth.org/. 

Carole Johnson, 

Administrator. 

[FR Doc. 2023–21514 Filed 9–28–23; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Eye Institute; Notice of Closed 

Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Eye Institute 

Special Emphasis Panel; Mentored Clinical 

Scientist Research Career Development 

Award (K08/K23) and Conference Grant 

(R13) Applications. 

Date: October 26, 2023. 

Time: 12:00 p.m. to 3:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Eye Institute, 6700 

Rockledge Drive, Bethesda, MD 20817 

(Virtual Meeting). 

Contact Person: Brian Hoshaw, Ph.D., 

Designated Federal Official, Division of 

Extramural Research, National Eye Institute, 

National Institutes of Health, 6700 B 

Rockledge Dr., Rockville, MD 20892, 301– 

451–2020, hoshawb@mail.nih.gov. 

Name of Committee: National Eye Institute 

Special Emphasis Panel; Pathways to 

Independence (K99) Applications. 

Date: November 6, 2023. 

Time: 11:00 a.m. to 4:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Eye Institute, 6700B 

Rockledge Drive, Bethesda, MD 20817 

(Virtual Meeting). 

Contact Person: Ashley Fortress, Ph.D., 

Designated Federal Official, Division of 

Extramural Activities, National Eye Institute, 

National Institutes of Health, 6700 B 

Rockledge Dr., Bethesda, MD 20817, (301) 

451–2020, ashley.fortress@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program No. 93.867, Vision Research, 

National Institutes of Health, HHS) 

Dated: September 25, 2023. 

Victoria E. Townsend, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–21490 Filed 9–28–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Nursing Research; 

Notice of Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the National Advisory 

Council for Nursing Research. 

This will be a hybrid meeting held inperson and virtually and will be open to 

the public as indicated below. 

Individuals who plan to attend inperson or view the virtual meeting and 

need special assistance or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. The meeting 

can be accessed from the NIH Videocast 

at the following link: https://

videocast.nih.gov/ 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Advisory 

Council for Nursing Research. 


lotter on DSK11XQN23PROD with NOTICES1